Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations.
Pingli Wang(Second Affiliated Hospital of Zhejiang University), Kai Wang(Michigan United), June Xu, Dongqing Lv(Wenzhou Medical University), Liming Cao(Central South University), Liyun Miao(Nanjing Drum Tower Hospital), Panwen Tian(Sichuan University), Yuping Li(Binzhou Medical University), Mei Yang(Tongji University), Xin Zhao(Soochow University), Yong Song(Nanjing General Hospital of Nanjing Military Command), Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Yun Fan(NOAA National Centers for Environmental Prediction), Chaonan Zhu, Shengxiang Ren(Tongji University)
Cited by 0
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Reduced default mode network functional connectivity in patients with recurrent major depressive disorder
|Proceedings of the National Academy of Sciences|2019|865
Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells
|Molecular Cancer|2011|700
Common variants at five new loci associated with early-onset inflammatory bowel disease
|Nature Genetics|2009|483